Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Forbes

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Trials|January 31, 2014
A rehabilitation intervention to promote physical recovery following intensive care: a detailed description of construct development, rationale and content together with proposed taxonomy to capture processes in a randomised controlled trialPam Ramsay, Lisa G Salisbury, Judith L Merriweather, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIIIJürg Bernhard, David Zahrieh, Monica Castiglione-Gertsch, et al.
Trials|October 8, 2011
Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians)Anne Douglas, Raj S Bhopal, Ruby Bhopal, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Stroke|April 18, 2020
Association Between Walking Pace and Stroke Incidence: Findings From the UK Biobank Prospective Cohort StudySara Hayes, John F Forbes, Carlos Celis-Morales, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
The New England Journal of Medicine|December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, Carl-Magnus Rudenstam, David Zahrieh, et al.
The Lancet. Oncology|October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Trials|January 31, 2014
A rehabilitation intervention to promote physical recovery following intensive care: a detailed description of construct development, rationale and content together with proposed taxonomy to capture processes in a randomised controlled trialPam Ramsay, Lisa G Salisbury, Judith L Merriweather, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIIIJürg Bernhard, David Zahrieh, Monica Castiglione-Gertsch, et al.
Trials|October 8, 2011
Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians)Anne Douglas, Raj S Bhopal, Ruby Bhopal, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Stroke|April 18, 2020
Association Between Walking Pace and Stroke Incidence: Findings From the UK Biobank Prospective Cohort StudySara Hayes, John F Forbes, Carlos Celis-Morales, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
The New England Journal of Medicine|December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2007
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trialHenning Mouridsen, Aparna Keshaviah, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, Carl-Magnus Rudenstam, David Zahrieh, et al.
The Lancet. Oncology|October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Pageof 9